JAZZ · NASDAQ · STOCK
Jazz Pharmaceuticals (JAZZ) Stock Analysis
$240.67
52W $125.79 – $266.38
57/100
$15.12B
15.8
0.32
Is JAZZ Bullish or Bearish?
Mixed.
Innellis AI committee rates Jazz Pharmaceuticals (JAZZ) Watch with a composite score of 57/100
, based on 5 analysts with 60% agreement.
Last updated September 20, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +2.73 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -17.27 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee sees neither a compelling opportunity nor a clear risk at this stage. Conditions remain neutral — patience is warranted.
Bull & Bear Case
Bull Case
- ROE of 21.4% shows genuine earnings power backing the valuation — Value
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 20, 2026
Overall Committee Score
57/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 46%
of 192 Healthcare peers
Value Analyst
bullish
63
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 21.4% shows genuine earnings power backing the valuation
Growth Analyst
neutral
50
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2518.64)
Investment Thesis Evolution
Committee score moved marginally from 57.3 to 57.3.
Comparing 2026-09-19 to 2026-09-20 (1 day apart).
Technical Analysis
RSI (14)
40.5
Neutral
MACD Histogram
-0.400
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$220.74
Resistance
$243.25
Bollinger %B
0.23
Inside Bands
Price vs Moving Averages
EMA 9
$243.38
Below
EMA 21
$245.52
Below
EMA 50
$244.98
Below
EMA 200
$212.44
Above
Fundamental Analysis
Valuation
90
Growth
59
Profitability
50
Financial Health
80
Cash Flow
70
Valuation
P/E Ratio
15.8×
P/B Ratio
3.17×
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$266.38
52W Low
$125.79
Quality & Growth
ROE
-824.7%
ROA
-305.5%
Gross Margin
8467.4%
Operating Margin
3105.1%
Revenue Growth YoY
—
Debt / Equity
0.92
AI Fundamental Assessment
P/E ratio of 15.8 (inexpensive relative to a 15-40x range); Price-to-book of 3.2x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -8.2%; Return on assets of -3.1%; Net margin of 20.4%; Gross margin of 84.7%; Current ratio of 1.78 (healthy short-term liquidity); Debt-to-equity of 0.92; Free cash flow per share is positive (24.40); Most recent quarter missed estimates by 9.4%; EPS growth decelerating (-4.5% -> -9.9% QoQ); Average YoY EPS growth of 169.2%; Analyst estimates falling over recent quarters
Get the Full JAZZ Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →